乌克兰2018-21年抗生素耐药性调查:基于CLSI、EUCAST和PK/PD折点的肺炎链球菌与流感嗜血杆菌药敏数据
该研究对2018-21年乌克兰社区获得性呼吸道感染分离的肺炎链球菌(n=64)和流感嗜血杆菌(n=76)进行CLSI微量肉汤稀释法药敏检测,并分别用CLSI、EUCAST(剂量特异性)和PK/PD折点判读。结果显示肺炎链球菌对氟喹诺酮类100%敏感,对第三代头孢菌素90.6%-96.9%敏感;流感嗜血杆菌对阿莫西林/克拉维酸、大环内酯类、多数头孢菌素和四环素按CLSI均100%敏感。作者认为结果与乌克兰既往耐药监测一致,持续监测对指导社区获得性呼吸道感染经验性治疗很重要。
要点
- 肺炎链球菌对氟喹诺酮类100%敏感,对第三代头孢菌素90.6%-96.9%敏感。
- 流感嗜血杆菌对阿莫西林/克拉维酸、大环内酯类、多数头孢菌素和四环素按CLSI均100%敏感。
- 不同折点体系(CLSI、EUCAST剂量特异性、PK/PD)判读结果存在差异,解读药敏时需注明所用折点。
核心结论
- 乌克兰2018-21年社区获得性呼吸道感染分离株对常用抗菌药物总体保持较高敏感性,但不同折点体系判读结果存在差异。
- 肺炎链球菌对氟喹诺酮类100%敏感,对第三代头孢菌素90.6%-96.9%敏感,对阿莫西林及阿莫西林/克拉维酸96.9%敏感。
- 流感嗜血杆菌对阿莫西林/克拉维酸、大环内酯类、多数头孢菌素和四环素按CLSI均100%敏感。
研究设计与样本
- 研究为抗生素耐药性调查(SOAR)2018-21年乌克兰部分,采用CLSI微量肉汤稀释法测定MIC。
- 共收集肺炎链球菌64株和流感嗜血杆菌76株,均来自社区获得性呼吸道感染。
- 药敏结果分别用CLSI、EUCAST(剂量特异性)和PK/PD折点判读。
主要发现
- 肺炎链球菌按CLSI口服/EUCAST低剂量折点青霉素敏感率为82.8%,按EUCAST高剂量/CLSI静脉折点为98.4%。
- 肺炎链球菌对阿莫西林、阿莫西林/克拉维酸和头孢菌素类CLSI敏感率为85.9%-96.9%,对四环素和大环内酯类为73.4%-76.6%,对甲氧苄啶/磺胺甲噁唑为59.4%。
- 肺炎链球菌按EUCAST高剂量方案判读敏感率相近,但甲氧苄啶/磺胺甲噁唑敏感率为79.7%。
- 流感嗜血杆菌中β-内酰胺酶阴性者为72株(94.7%),除甲氧苄啶/磺胺甲噁唑外敏感率均>94.7%。
- 流感嗜血杆菌对甲氧苄啶/磺胺甲噁唑敏感率按CLSI/EUCAST低剂量为61.8%、按EUCAST高剂量为68.4%。
关键数值与推荐
- 肺炎链球菌对氟喹诺酮类敏感率为100%。
- 流感嗜血杆菌按EUCAST判读时口服头孢呋辛敏感率为0%,而按CLSI为100%。
- 流感嗜血杆菌按PK/PD折点判读时头孢克洛敏感率为11.8%。
临床怎么用
- 社区获得性呼吸道感染经验性治疗可参考当地药敏监测数据选择药物。
- 解读药敏报告时需注意所用折点体系(CLSI、EUCAST剂量特异性或PK/PD),不同体系结果可能差异显著。
- 对甲氧苄啶/磺胺甲噁唑等敏感率较低的药物,经验性使用需谨慎并结合本地数据。
局限性
- 肺炎链球菌(n=64)和流感嗜血杆菌(n=76)样本量较小,结果外推需谨慎。
- 研究仅纳入2018-21年乌克兰分离株,结论受地区和时段限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory tract infections (CA-RTIs) collected in 2018-21 from Ukraine. METHODS: MICs were determined by CLSI broth microdilution test, and susceptibility data were interpreted using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae (n = 64) and H. influenzae (n = 76) isolates were collected in 2018-21. Antibiotic susceptibility was 82.8% for pneumococci penicillin-susceptible by CLSI oral/EUCAST low-dose breakpoints and 98.4% by EUCAST high-dose/CLSI intravenous breakpoints. Fluoroquinolones were the most active (100% susceptible). CLSI susceptibility of 85.9%-96.9% was also observed for amoxicillin, amoxicillin/clavulanic acid and cephalosporins. Tetracycline and macrolide susceptibility was 73.4%-76.6%, and trimethoprim/sulfamethoxazole was 59.4%. EUCAST susceptibility was similar if high-dose regimens were chosen, although susceptibility to trimethoprim/sulfamethoxazole was 79.7%. Most H. influenzae isolates were β-lactamase negative (n = 72, 94.7%) with >94.7% susceptibility, except for trimethoprim/sulfamethoxazole (61.8% by CLSI/EUCAST low-dose, 68.4% by EUCAST high-dose). Susceptibility using EUCAST breakpoints was similar to CLSI, except cefuroxime (oral) with 0% of isolates susceptible versus 100% by CLSI. Cefaclor susceptibility was 11.8% using PK/PD breakpoints. CONCLUSIONS: For H. influenzae, 100% susceptibility (CLSI) was observed to amoxicillin/clavulanic acid, macrolides, most cephalosporins and tetracycline. S. pneumoniae susceptibility was 100% to fluoroquinolones, 90.6%-96.9% to third-generation cephalosporins and 96.9% to amoxicillin and amoxicillin/clavulanic acid. This is consistent with previous resistance surveillance in Ukraine. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs.
引用
- Torumkuney D, Bratus E, Yuvko O, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277339. doi:10.1093/jac/dkaf287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。